Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 15 h ago

PMV Pharmaceuticals, Inc.: TANG CAPITAL MANAGEMENT LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

TANG CAPITAL MANAGEMENT LLC amended its Schedule 13G filing for PMV Pharmaceuticals, Inc., updating its beneficial ownership stake with the SEC under accession number 0001214659-26-014414. The amendment signals a change in the investment firm's position in the clinical-stage oncology company, though the filing's headline disclosure did not specify the revised share count or percentage. Schedule 13G amendments are typically filed by passive investors and are closely watched for shifts in institutional backing of small-cap biotech names. Investors will look to the full filing for the exact size and direction of TANG's stake change, and to any subsequent 13F or 13D activity for signs of a more active posture toward PMV.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

PMV Pharmaceuticals, Inc., TANG CAPITAL MANAGEMENT LLC